Fig 7.

Repeat exposure to griffithsin does not increase susceptibility to HSV-2 in a murine model. Mice were pretreated with medroxyprogesterone acetate; 5 days later, mice received one 20-μl dose of 0.1% GRFT, Carbopol, or 4% N-9 gel intravaginally daily for 7 days. On the eighth day, a vaginal wash was taken to remove residual drug and to test for residual anti-HIV activity in a TZM-bl assay; results are means (SEM) from 3 pools of vaginal washes, each pool containing washes from 2 mice, conducted in triplicate. (A) Data are plotted as percentages of virus control. Asterisk indicates P values of <0.05 compared to washes from Carbopol-treated mice (unpaired t test). Mice were then challenged with HSV-2(4674) diluted in 30 μl PBS at LD₁₀ (B), LD₅₀ (C), or LD₉₀ (D), with 10 to 20 mice per group. Mice were scored for disease daily and were sacrificed if indicated by disease scores. Kaplan-Meier survival curves are shown; asterisks indicate P values of <0.05 (log rank test), compared to Carbopol treatment.